Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global CD137 Antibodies Market Opportunity, Therapeutic Approaches, Technology Development Platforms and Clinical Trials Insight 2026 Report Highlights:

First CD137 Antibody Commercial Launch Expected By 2030
Insight On CD137 Antibodies In Clinical Trials: > 90 Antibodies
CD137 Antibodies Clinical Trials Insight By Company, Country, Indication and Phase
Highest Clinical Trials Phase: Phase III
CD137 Therapies Proprietary Technology Platforms By Companies
Global and Regional Trends (Clinical and Commercial)
Therapeutic Approaches For Targeting CD137

CD137 Targeted Therapies Need and Why This Report?

CD137 or 4-1BB, is a co-stimulatory receptor important for T-cell activation, survival, and expansion. It is also recognized for playing a critical role in augmenting anti-tumor immune responses, hence becoming one of the most valued targets in cancer immunotherapy. Notwithstanding recent progress made in immune-oncology, current treatments such as chemotherapy and immune checkpoint inhibitors have some shortcomings regarding their efficacy among patients, especially those with solid tumors. CD137-targeting therapies can bridge these gaps through the direct stimulation of immune cells in the tumor microenvironment, leveraging the body to better combat cancer.

The report covers the increasing enthusiasm for CD137-targeted therapies, underlining the details of ongoing clinical trials, emerging technologies, and identifying companies that are driving the innovation process. It underlines the therapeutic potential of CD137 modulation in oncology: from describing progress made at different stages of clinical development to outlining the competitive and scientific landscape forming the future for various CD137-targeted treatment strategies.

Clinical Studies and Trials Insight Included In Report

The report provides comprehensive insights into the ongoing clinical studies and trials for CD137 targeted therapies, enabling stakeholders to take a clear view of the therapeutic progress of this field. An analysis is provided of various clinical stages that range from early-phase trials to more advanced studies. These trials involve research into a range of indications, with particular attention to solid tumors and hematological malignancies. Ongoing combination therapy trials are also discussed, concerned with the investigation into how agents targeting CD137 may act in concert with chemotherapies or other immunotherapies-including PD-1 or VEGF inhibitors-to improve overall efficacy. This review also identifies the emerging clinical data and assesses the safety and efficacy profiles of CD137-targeted therapies, providing critical insight into the way forward for these therapies.

Technology Platforms Included In Report

The report further profiles technology platforms driving innovations in CD137 targeted therapy development. Examples include AP Biosciences' T-cube, a platform enabling the creation of bispecific antibodies that selectively activate T-cells through CD137 only upon binding to tumor-specific antigens. This specificity offers the promise of minimal off-target toxicities, such as cytokine storms, common with other immune therapies. These technology platforms represent a quantum leap in cancer immunotherapy by providing an enabling environment for more targeted, safer, and probably more effective therapies. The report provides an overview of such platforms and assesses their implications for future CD137-targeted therapies.

Leading Companies Involved In RandD of CD137 Targeted Therapies

Established pharmaceutical giants and emerging biotech companies both lead in the development of CD137-targeted therapies. Major players such as Roche, Genmab, and Sichuan Baili Pharmaceutical are actively advancing their CD137-targeting therapies in clinical trials. Smaller firms like ABL Bio and Pieris Pharmaceuticals continue to bring in diversity into the research landscape by exploring novel bispecific antibodies and delivery systems. This report describes those key companies, insights into their pipelines and strategies, and the progress of their CD137-targeted therapies in order to give a clear picture of the competitive landscape in this rapidly evolving field.

Report Indicating Future Direction of CD137 Targeted Therapies

Looking ahead, the report comprehensively analyzes the future direction of CD137-targeted therapies. The landscape is continuously evolving, with new innovations likely to overcome some of the existing challenges related to immune resistance and side effects such as cytokine release syndrome. Furthermore, combination therapies that combine CD137 agonists with other immune checkpoint inhibitors or targeted treatments offer significant potential for overcoming limitations observed in monotherapies. In the context of ongoing clinical trials and the emergence of new data, the role of CD137-targeted therapies is likely to be increasingly important in cancer treatment. This report provides key insights into these emerging trends, enabling stakeholders to anticipate the future direction of this promising field and its likely impact on the oncology landscape.

Research Methodology

Brief Introduction To CD137

2.1 Clinical Overview

2.2 Biological History Of CD137

2.3 CD137 Hosting An Era Of Agonists Over Antagonists

2.4 Bi-Directional Signaling In CD137

Global CD137 Targeting Therapy Market Outlook

3.1 Current Research and Market Scenario

3.2 Future Commercialization Opportunities

CD137 Targeting Therapy Clinical Innovation Trends By Region

4.1 China

4.2 South Korea

4.3 US

4.4 Europe

4.5 Australia

CD137 Role and Clinical Progress By Indication

5.1 Cancer

5.1.1 Leukemia

5.1.2 Lymphoma

5.1.3 Lung Cancer

5.1.4 Melanoma

5.1.5 Breast Cancer

5.1.6 Colorectal Cancer

5.2 Autoimmune and Inflammatory Diseases

5.3 Microbial Infections

5.4 Neuronal Diseases

Global CD137 Targeting Therapy Clinical Trials Overview

6.1 By Company

6.2 By Country

6.3 By Indication

6.4 By Phase

CD137 Targeting Therapy Clinical Trials Insight By Company, Country, Indication and Phase

7.1 Research

7.2 Preclinical

7.3 Phase I

7.4 Phase I/II

7.5 Phase II

7.6 Phase III

CD137 Therapies Proprietary Technology Platforms By Companies

Therapeutic Approaches For Targeting CD137

9.1 Antibodies

9.1.1 Monoclonal antibodies

9.1.2 Bispecific Antibody Centered Approaches

9.1.3 Trispecific Antibody Established Strategies

9.1.4 Tetraspecific Antibody Strategies

9.1.5 Single-chain variable fragments

9.2 Peptides

9.3 Protein-Based Therapeutics

Combination Therapies With CD137 Targeting Therapies

Competitive Landscape

11.1 ABL Bio

11.2 Adagene

11.3 Alligator Bioscience

11.4 BeOne Medicines

11.5 Bicycle Therapeutics

11.6 BioNTech

11.7 Crescendo Biologics

11.8 Compass Therapeutics

11.9 Eutilex

11.10 F-star Therapeutics

11.11 Genmab

11.12 NovaBridge Biosciences

11.13 Kyinno Biotechnology

11.14 Lyvgen Biopharma

11.15 Obsidian Therapeutics

11.16 OriCell Therapeutics

11.17 Palvella Therapeutics

11.18 Shanghai Henlius Biotech

11.19 Sichuan Baili Pharmaceutical

11.20 SystImmune

Figure 2-1: Evolution Of Cancer Immunotherapy Approaches

Figure 2-2: Biological Effects Triggered By CD137 Stimulation

Figure 2-3: CD137 - Discovery and Early Biological Characterization

Figure 2-4: Mechanistic Pathways Triggered By CD137 Ligation

Figure 2-5: Anti-CD137 Monoclonal Antibody - Immune Regulation Mechanisms

Figure 2-6: Why CD137 Became An Important Target

Figure 2-7: Schematic Depiction Of Bidirectional Signaling By CD137–CD137L

Figure 2-8: CD137 - Forward Signaling Cascade in Immune Cells

Figure 2-9: CD137L - Reverse Signaling

Figure 2-10: Bidirectional Signaling Loop Between CD137 and CD137L

Figure 3-1: Global CD137 Targeting Therapy Market - Future Opportunities

Figure 5-1: Bidirectional CD137–CD137L Signaling in Leukemia Cell Survival

Figure 5-2: GNC-035-105 Phase Ib/II (NCT05944978) Study – Initiation and Completion Year

Figure 5-3: GNC-035-105 Phase I/II (NCT05944978) Study – Initiation and Completion Year

Figure 5-4: GNC-038-101 Phase I (NCT04606433) Study – Initiation and Completion Year

Figure 5-5: Lymphoma - CD137’s Role In Countering Immune Evasion

Figure 5-6: BP41072 Phase I/II (NCT04077723) Study – Initiation and Completion Year

Figure 5-7: YH004 Phase I (NCT05564806) Study – Initiation and Completion Year

Figure 5-8: IBD0333-101 Phase I/II (NCT06292208) Study – Initiation and Completion Year

Figure 5-9: Lung Cancer - Rationale For Targeting CD137

Figure 5-10: BT7480-100 Phase I/II (NCT05163041) Study – Initiation and Completion Year

Figure 5-11: GCT1046-04 Phase 2 (NCT05117242) Study – Initiation and Completion Year

Figure 5-12: HLX35-FIH101 Phase I (NCT05360381) Study – Initiation and Completion Year

Figure 5-13: EU-CTS101-I-01 Phase I/II (NCT04903873) Study – Initiation and Completion Year

Figure 5-14: Melanoma - CD137 As A Costimulatory Driver Of Disease Immunity

Figure 5-15: FS222-19101 Phase I (NCT04740424) Study – Initiation and Completion Year

Figure 5-16: LBL-024-CN007 Phase I/II (NCT07099430) Study – Initiation and Completion Year

Figure 5-17: ABBIL1TY MELANOMA-07 Phase II (NCT06984328) Study – Initiation and Completion Year

Figure 5-18: Breast Cancer - Dual Role Of CD137 In Disease Biology

Figure 5-19: BT7480-100 Phase I/II (NCT05163041) Study – Initiation and Completion Year

Figure 5-20: AP402-101 Phase I/II (NCT06669975) Study – Initiation and Completion Year

Figure 5-21: AVIATOR Phase 2 (NCT03414658) Study – Initiation and Completion Year

Figure 5-22: ADG106-T6002 Phase 1/2 (NCT05275777) Study – Initiation and Completion Year

Figure 5-23: YH32367-101 Phase I/II (NCT05523947) Study – Initiation and Completion Year

Figure 5-24: GNC-035-103 Phase II (NCT05160545) Study – Initiation and Completion Year

Figure 5-25: EU-CTS101-I-01 Phase I/II (NCT04903873) Study – Initiation and Completion Year

Figure 5-26: 2017-0180 Phase 1 (NCT03290937) Study – Initiation and Completion Year

Figure 5-27: 1002-CL-0101 Phase I (NCT05719558) Study – Initiation and Completion Year

Figure 5-28: BNT314-02 Phase I/II (NCT07079631) Study – Initiation and Completion Year

Figure 5-29: CD137 - Dual Role In Immune Regulation

Figure 5-30: Microbial Infections - CD137 Expression and Immune Roles

Figure 5-31: CD137 In Neuroinflammation

Figure 6-1: Global – CD137 Targeting Antibodies Clinical Pipeline by Company (Numbers), 2026

Figure 6-2: Global – CD137 Targeting Antibodies Clinical Pipeline by Country (Numbers), 2026

Figure 6-3: Global – CD137 Targeting Antibodies Clinical Pipeline by Indication (Numbers), 2026

Figure 6-4: Global – CD137 Targeting Antibodies Clinical Pipeline by Phase (Numbers), 2026

Figure 8-1: Adagene – Anti CD137 NEObody ACG106

Figure 8-2: Adagene – Anti CD137 POWERbody ADG206

Figure 8-3: Genmab - DUObody Production Process

Figure 8-4: Genmab - DUObody Platform Detail

Figure 8-5: Crescendo Biologics - Humabody Structure

Figure 8-6: CB307 Humabody – Structure

Figure 8-7: Numab Therapeutics - MATCH Format

Figure 8-8: NM21-1480 - Structure

Figure 8-9: Systimmune – GNC-039 Structure

Figure 8-10: Systimmune – GNC-035 Structure

Figure 8-11: Systimmune – GNC-038 Structure

Figure 8-12: Merus – Multiclonics Structure

Figure 8-13: Chugai Pharmabody Research - Dual-Igandreg; Technology

Figure 8-14: Eutilex - Costim Platform Technology

Figure 8-15: AND-Body - Ampersand Biomedicines

Figure 8-16: X-body Platform - Leads Biolabs

Figure 8-17: T-cube Bispecific Antibody Platform - AP Biosciences

Figure 8-18: Grabody-T - ABL Bio

Figure 8-19: LEAD-452 Trimerbody – Structure

Figure 9-1: ATOR-1017 – Mechanism Of Action

Figure 9-2: EU101 – Mode Of Action

Figure 9-3: LVGN6051 – Mechanism Of Action

Figure 9-4: Ragistomig – Structure and Mechanism Of Action

Figure 9-5: FS120 – Improving PD-1 and Chemotherapy Responses

Figure 9-6: FS222 – Structure

Figure 9-7: FS222 – Mechanism Of Action

Figure 9-8: MP0310 – Mechanism Of Action

Figure 9-9: CD137 Targeting GNC Tetraspecific Antibodies

Figure 9-10: CD137 Targeting Peptide - Mechanism

Figure 9-11: CD137 Targeting Fusion Protein - Conditional Activation Design

List Of Tables

Table 2-1: CD137 Expression Across Cell Types

Table 2-2: Comparison Of Antagonistic vs Agonistic Immunotherapies

Table 5-1: Lymphoma – Clinical Trials Underway for GNC-038 and GNC-035

Table 9-1: Some Bispecific Antibodies Targeting CD137 In Development

Table 9-2: Some Trispecific Antibodies Targeting CD137 In Development

Table 9-3: Some Tetraspecific Antibodies Targeting CD137 In Development

Table 10-1: Ongoing Clinical Trials Evaluating CD137 Antibody Combinations

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global CD137 Antibodies Market Opportunity, Therapeutic Approaches, Technology Development Platforms and Clinical Trials Insight 2026

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected